SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

SAN

81.95

+1.6%↑

UCB

262.1

+1.67%↑

SHL.DE

38.94

+1.54%↑

ARGX

717.6

+0.96%↑

VIE

35.55

+0.74%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fermé

SecteurSoins de santé

85.1 1.49

Résumé

Variation du prix de l'action

24h

Actuel

Min

83.85

Max

85.35

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

35.869

63.808

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+2.54% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

353M

4.3B

Ouverture précédente

83.61

Clôture précédente

85.1

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 avr. 2026, 20:26 UTC

Acquisitions, Fusions, Rachats

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 avr. 2026, 18:15 UTC

Principaux Événements d'Actualité

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 avr. 2026, 16:49 UTC

Principaux Événements d'Actualité

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 avr. 2026, 16:49 UTC

Principaux Événements d'Actualité

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 avr. 2026, 22:58 UTC

Résultats

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 avr. 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 avr. 2026, 20:52 UTC

Résultats

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 avr. 2026, 20:50 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

17 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 avr. 2026, 20:29 UTC

Résultats

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 avr. 2026, 20:11 UTC

Acquisitions, Fusions, Rachats

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 avr. 2026, 19:34 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

17 avr. 2026, 19:34 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 avr. 2026, 19:31 UTC

Market Talk
Principaux Événements d'Actualité

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 avr. 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 avr. 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 avr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 avr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 avr. 2026, 18:57 UTC

Principaux Événements d'Actualité

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 avr. 2026, 18:53 UTC

Acquisitions, Fusions, Rachats

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 avr. 2026, 18:53 UTC

Acquisitions, Fusions, Rachats

UCB 2026 Rev Guidance Unchanged

17 avr. 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 avr. 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 avr. 2026, 18:14 UTC

Market Talk
Principaux Événements d'Actualité

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 avr. 2026, 18:00 UTC

Principaux Événements d'Actualité

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 avr. 2026, 18:00 UTC

Principaux Événements d'Actualité

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 avr. 2026, 17:31 UTC

Market Talk
Principaux Événements d'Actualité

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 avr. 2026, 17:26 UTC

Market Talk
Résultats

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

2.54% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  2.54%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat